In an unbiased biomarker discovery approach , we applied a highly multiplexed , aptamer-based , proteomic technology to analyze serum samples collected at baseline and after @ weeks of treatment from @ patients with pulmonary TB from Kampala , Uganda enrolled in a Centers for Disease Control and Prevention ( CDC ) TB Trials Consortium Phase @B treatment trial .